Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 15/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 15/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458127 | 0.84 | GRM2 (0.38) | PDE3BPDE3A | |
| SCHEMBL4472192 | 0.84 | GRM2 (0.35) | PDE3BPDE3A | |
| SCHEMBL4454827 | 0.83 | ESR2 (0.39) | PDE3BPDE3A | |
| SCHEMBL4447352 | 0.81 | GRM2 (0.37) | — | |
| SCHEMBL4469790 | 0.81 | PTGDR2 (0.35) | PDE3BPDE3A | |
| SCHEMBL4445385 | 0.81 | PGR (0.40) | — | |
| SCHEMBL4453552 | 0.79 | BRD4 (0.35) | — | |
| SCHEMBL4445299 | 0.78 | ALDH1A1 (0.39) | — | |
| SCHEMBL4460630 | 0.78 | GRM2 (0.41) | — | |
| SCHEMBL4452503 | 0.76 | P2RX7 (0.39) | PDE3BPDE3AS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | PDE3B 59/4885PDE3A 87/4885S1PR1 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.